A Phase 2 interventional study of Nebivolol 5 mg in HER2-positive Breast Cancer, sponsored by Ain Shams University. Recruiting at 1 site in Egypt. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-11-19.
Sponsored by Ain Shams University · Phase 2, Interventional, and Prevention
How we know · 3 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Breast Neoplasms by Ain Shams University — 9 open to participants now, 10 under way, none of them phase 3. Breast Neoplasms · Ain Shams University.
Among the 26 studies in Breast Neoplasms by Ain Shams University, this one is the 10th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2025, is one of 4 in phase 2, and was the 24th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →9 of the 26 studies in Breast Neoplasms by Ain Shams University are open now, in 1 country. Recruiting first, the newest first:
Ain Shams University · Sites in Egypt
Ages 30–50 · Women only
Ain Shams University · Sites in Egypt
Ages 18+ · Women only · Healthy volunteers
Ain Shams University · Sites in Egypt
Ages 18+ · Women only
Ain Shams University · Sites in Egypt
Ages 18–75 · Women only
Ain Shams University · Sites in Egypt
Ages 18–75 · Women only
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years to 65 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 2 · Phase 4 1
First in 2012; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 56 is below the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 80 across the 12 interventional studies, 94 across the 14 observational. Of the 9 that completed or were terminated, 1 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
Ain Shams University is the lead sponsor of 1,958 studies on the registry; 432 are open to participants now.
Of its 35 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
1 of the studies in Breast Neoplasms by Ain Shams University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07233499Ain Shams UniversityEvaluation of the Cardioprotective Effect of Nebivolol on Trastuzumab-Induced Cardiotoxicity in Breast Cancer Patients | 2027-02-01 |
Add it to your calendar (.ics) → With an account.
Among the 26 studies in Breast Neoplasms by Ain Shams University, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Breast cancer can be managed using chemotherapy, endocrine therapy and biological therapy. Treatment is determined and specified according to the characteristics of the tumor including overexpression of the human epidermal growth factor receptor (HER2). Previously patients who were diagnosed with HER2 positive breast cancer were considered of poor survival but after the discovery of trastuzumab, disease free survival among these patients was improved significantly.
Though trastuzumab has made great improvement in the treatment of breast cancer, it was identified to possess a major side effect which is cardiotoxicity . Cardiotoxicity that occurs with anticancer agents is usually manifested as left ventricular dysfunction (LVD) and overt heart failure (HF). LVD was defined as a decrease in cardiac LV ejection fraction (LVEF), that is either global or more severe in the septum, symptoms of congestive heart failure (CHF), associated signs of CHF including but not limited to S3 gallop, tachycardia or both and decline in LVEF of at least 5% to below 55% with accompanying signs or symptoms of CHF, or a decline in LVEF of at least 10% to below 55% without accompanying signs or symptoms.
Beta blockers have shown a cardioprotective effect against chemotherapy induced- cardiotoxicity.
Nebivolol is a third-generation beta blocker. It is highly selective to B1- adrenergic receptors. It also has peripheral vasodilating effect due to its effect on L-arginine/ nitric oxide pathway in the endothelium of blood vessels.
The dose of nebivolol given in the study was 5mg/day for the entire period of the study. Echo was done for all patients to determine the changes of left ventricular ejection fraction in patients in the treatment group and control group. The study concluded that nebivolol prevented the occurrence of anthracycline induced cardiotoxicity.
the current study will be the first clinical trial to evaluate the cardioprotective effect of nebivolol on trastuzumab-induced cardiotoxicity in breast cancer patients.
Aim of the work
Evaluation of the effect of Nebivolol on trastuzumab - induced cardiotoxicity in non-metastatic breast cancer patients by assessment of:
Breast cancer is one of the most common malignancies that affect females around the world. According to the WHO, the number of females who were diagnosed with breast cancer in 2020 in Egypt was 22038 females. This number represents 32.4% of all women malignancies and 16.4% of all malignancies in Egypt (men and women).
Breast cancer can be managed using chemotherapy, endocrine therapy and biological therapy. Treatment is determined and specified according to the characteristics of the tumor including overexpression of the human epidermal growth factor receptor (HER2). Previously patients who were diagnosed with HER2 positive breast cancer were considered of poor survival but after the discovery of trastuzumab, disease free survival among these patients was improved significantly.
Trastuzumab is a humanized monoclonal antibody that was approved to treat HER2 positive breast cancer. Studies have shown that trastuzumab has improved the survival, reduced the mortality, reduced the recurrence and metastases rates in patients with HER2 positive breast cancer. Trastuzumab perform its tumor suppressive actions through different mechanisms that include activation of antibody-dependent cell-mediated cytotoxicity, inhibition of HER2 extracellular domain cleavage, disruption of HER2 receptor homodimerization and heterodimerization, abrogation of oncogenic cellular signaling and downregulation of angiogenesis and DNA repair pathways.
Though trastuzumab has made great improvement in the treatment of breast cancer, it was identified to possess a major side effect which is cardiotoxicity. Cardiotoxicity that occurs with anticancer agents is usually manifested as left ventricular dysfunction (LVD) and overt heart failure (HF). LVD was defined as a decrease in cardiac LV ejection fraction (LVEF), that is either global or more severe in the septum, symptoms of congestive heart failure (CHF), associated signs of CHF including but not limited to S3 gallop, tachycardia or both and decline in LVEF of at least 5% to below 55% with accompanying signs or symptoms of CHF, or a decline in LVEF of at least 10% to below 55% without accompanying signs or symptoms.
According to a study conducted by Mohan et al in 2016, It was shown that treatment with trastuzumab leads to inhibition of HER2 signaling and phosphorylation of HER1-Y845/HER2-Y1248 and the activation of Erk. All this consequently leads to upregulation of the mTOR-Ulk1 pathway to mediate inhibition of autophagy in cardiomyocytes. This was clearly shown by the decrease in expression levels of LC3 I/II and increase in p62 after trastuzumab treatment. Studies has shown that inhibition of autophagy by autophagy inhibitor (3-methyladenine) leads to accumulation of damaged mitochondria and increase the concentration of mitochondrial ROS and thus accumulation of toxic reactive oxygen species (ROS) in human cardiomyocytes which can lead to oxidative damage and cardiotoxicity.
Beta blockers have been used to treat ischemic heart disease due to their negative chronotropic and inotropic properties thus inducing a decrease in myocardial consumption of oxygen and nutrients allowing better balance between nutritional needs and blood flow. Recent studies have proved that not all beta blockers have equal effect as their intercellular mechanisms of action are different. Beta blockers have shown a cardioprotective effect against chemotherapy induced- cardiotoxicity.
Nebivolol is a third-generation beta blocker. It is highly selective to B1- adrenergic receptors. It also has peripheral vasodilating effect due to its effect on L-arginine/ nitric oxide pathway in the endothelium of blood vessels. Nitric oxide is a paracrine factor derived from the endothelial cells and alleviate ROS mediated oxidative damage. Nebivolol activates the endothelial nitric oxide system and increases nitric oxide release through activation of the beta 3 adrenergic receptors in endothelium cells. The release of nitric oxide causes peripheral vasodilation, an increase in the myocardial compliance and an inhibition of inotropic effect of sympathetic stimulation. Nebivolol also decreases the nitric oxide break down and increases its bioavailability. All these effects of nebivolol on nitric oxide lead to a decrease in cardiac load, an enhanced cardiac filling and a protection of myocardium.
In a meta-analysis of 12 clinical trials, it was found that there was a great decrease in reactive oxygen species (ROS) concentration in endothelial cells exposed to oxidative stress in patients who were taking nebivolol in comparison to other patients who were receiving other beta blockers. Besides, it was found that the decrease of basal and stimulated nitric oxide because of oxidative stress is less in patients taking nebivolol compared to other patients. This all shows that nebivolol has antioxidant properties which reduce oxidative stress and affects organs damage.
The animal study which is conducted in 2018 to assess the Protective effect of nebivolol on doxorubicin-induced cardiotoxicity in rats. The specimens were examined using H + E and Masson's trichrome, caspase 3, endothelial nitric oxide synthase (eNOS), inducible nitric oxide synthase (iNOS) and tumor necrosis factor factor-α (TNF-α). The mean area percentage of collagen fiber content, caspase-3, eNOS, iNOS and TNF-α immunoactivities was measured. Doxorubicin-treated group showed marked myocyte distortion and fragmentation, congestion and cytoplasmic lysis in most fibers. These changes were less intense in the nebivolol-treated group. The study concluded that nebivolol exerted a significant protective effect from doxorubicin toxicity. The protective effect appears to be mediated mainly through caspase-3, eNOS, iNOS and TNF-α modulation.
Cochera and his colleagues conducted a study in 2018 to assess the effect of nebivolol treatment in the prevention of anthracyclines induced cardiotoxicity. The dose of nebivolol given in the study was 5mg/day for the entire period of the study. Echo was done for all patients to determine the changes of left ventricular ejection fraction in patients in the treatment group and control group. The study concluded that nebivolol prevented the occurrence of anthracycline induced cardiotoxicity.
the current study will be the first clinical trial to evaluate the cardioprotective effect of nebivolol on trastuzumab-induced cardiotoxicity in breast cancer patients.
Aim of the work
Evaluation of the effect of Nebivolol on trastuzumab - induced cardiotoxicity in non-metastatic breast cancer patients by assessment of:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Elderly patients( ˃65 years).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Nebivolol group (28 patients): will receive nebivolol at a dose of 5 mg once daily (orally) during the whole period of receiving trastuzumab
Drug: Nebivolol 5 mg
Control group (28 patients): will receive no intervention during the trastuzumab therapy
nebivolol tablet 5 mg once daily
This study also gives TrastuzumabStudies of TrastuzumabTrastuzumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.
Measurement of Left ventricular ejection fraction by Echocardiography
Echo will be done at baseline (before start of trastuzumab) and every 3 months during receiving trastuzumab to evaluate the reduction in the left ventricular ejection fraction and overall cardiac function
Time frame: 12 months
II-Evaluation of cardiac biomarkers.
Serum and plasma samples will be withdrawn from every patient at baseline, before surgery , after surgery and at the end of the study. Serum samples for evaluation of troponin and plasma samples for evaluation of pro-BNP. The samples will be stored at -20 till analysis.
Time frame: 12 months
Number of participants with treatment-related adverse events
Patients 'blood samples will be taken at baseline, 6 months and 12 months to check their liver functions, kidney functions and CBC. Nebivolol side effects will be followed up during regular phone calls with the patients every two weeks. the number of participants with adverse events will be recorded
Time frame: 12 months.
Evaluation of Quality of Life.
● The quality of life will be assed using Functional assessment of cancer therapy-Breast (FACT-B) at baseline, after 6 months and at the end of the study. the questionnaire assesses functional, social , physical and emotional well being. The score ranges from 0-148 with higher scores indicating better quality of life
Time frame: 12 months
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2025 (actual). Primary completion is estimated for Feb 2027, 25 months after the start.
Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 25 months is below that.
Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nebivolol